Adalimumab 80 mg ( DrugBank: Adalimumab )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	2

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,325 /  Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01270035 (ClinicalTrials.gov)	January 2011	4/1/2011	Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate		Rheumatoid Arthritis	Drug: Adalimumab	Keio University	Saitama Medical University	Recruiting	N/A	N/A	Both	40	Phase 4	Japan
2	NCT00538902 (ClinicalTrials.gov)	August 2007	1/10/2007	Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate	A Multi-center Randomized, Phase 2/3, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Safety and Efficacy of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate	Rheumatoid Arthritis	Biological: Placebo;Biological: Adalimumab 80 mg;Biological: Adalimumab 40 mg	Abbott	NULL	Completed	18 Years	N/A	All	302	Phase 2/Phase 3	China